The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV

Chris Wynne, Paul Hamilton, Jingxin Li, Chen Mo, Jiaping Yu, Wenrong Yao, Zijing Yue, Xi Zhang, Jianhui Zhang, Kunxue Hong, Jianping Chen, Yong Liu, Fengcai Zhu
doi: https://doi.org/10.1101/2022.05.11.22274932

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Back to top
Posted May 14, 2022.
Download PDF

Supplementary Material

Data/Code
Email
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
Chris Wynne, Paul Hamilton, Jingxin Li, Chen Mo, Jiaping Yu, Wenrong Yao, Zijing Yue, Xi Zhang, Jianhui Zhang, Kunxue Hong, Jianping Chen, Yong Liu, Fengcai Zhu
medRxiv 2022.05.11.22274932; doi: https://doi.org/10.1101/2022.05.11.22274932
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area